Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of EN001 in Charcot-Marie-Tooth Disease Type 1E
NCT06218134Completed
- Sponsor
- Samsung Medical Center
- Start
- May 2024
- Primary completion
- Oct 2024
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Open-label, single-arm trial of EN001 in Charcot-Marie-Tooth disease type 1E (CMT1E), sponsored by Samsung Medical Center. Primary endpoint: Infusion-related reaction at 12 months. Started May 2024; status: completed.
02
Drugs
EN001
03
Conditions
Charcot-Marie-Tooth disease type 1E (CMT1E)
Beyond the preview
Go deeper on NCT06218134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06218134.